Silas Inman | Authors

TILs Show Better PFS vs Ipilimumab in Unresectable Melanoma

September 10, 2022

A randomized phase 3 trial presented at 2022 ESMO revealed better progression-free survival outcomes with tumor-infiltrating lymphocytes vs ipilimumab in stage IIIC/IV unresectable, treatment-refractory melanoma.